- Home
- WF vs BBIO Comparison
WF vs BBIO Comparison
Compare WF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WF | BBIO |
|---|---|---|
| Founded | 1899 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 15.3B |
| IPO Year | 2003 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WF | BBIO |
|---|---|---|
| Price | $69.09 | $76.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 25 |
| Target Price | N/A | ★ $86.04 |
| AVG Volume (30 Days) | 115.3K | ★ 1.5M |
| Earning Date | 04-24-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $17.38 | $88.16 |
| Revenue Next Year | $4.24 | $74.13 |
| P/E Ratio | $9.03 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $33.21 | $31.77 |
| 52 Week High | $84.71 | $84.94 |
Technical Indicators
Market Signals| Indicator | WF | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 60.48 |
| Support Level | $51.38 | $69.62 |
| Resistance Level | N/A | $78.20 |
| Average True Range (ATR) | 2.02 | 2.73 |
| MACD | 0.49 | 0.54 |
| Stochastic Oscillator | 83.95 | 97.29 |
Price Performance
Historical ComparisonAbout WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.